

1600

1614

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184



TECH CENTER 1600/2900

APR 03 2002

TECH CENTER 1600/2900
RECEIVED
HOUSTON
WASHINGTON
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
CHICAGO
PHILADELPHIA
ATLANTA
SEATTLE
DENVER
SAN FRANCISCO
PORTLAND
SAN JOSE
SILICON VALLEY
MILWAUKEE
INDIANAPOLIS
COLUMBUS
CINCINNATI
CLEVELAND
DETROIT
KANSAS CITY
MEMPHIS
NASHVILLE
NEW ORLEANS
OKLAHOMA CITY
OMAHA
PITTSBURGH
RICHMOND
ST. LOUIS
TAMPA
WASHINGTON DC
WICHITA
WYOMING

FEB 14 2002

RECEIVED

January 30, 2002

FILE: UTSC:646US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 30, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/910,681 "REGULATED GROWTH FACTOR DELIVERY FOR ENGINEERED PERIPHERAL NERVE" – Gregory R.D. Evans et al. (Client Reference: MDA00-013)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A7, B1-B3, C1-C34).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10106337/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb

Encl: as noted

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Gregory R.D. Evans *et al.*

Serial No.: 09/910,681

Filed: July 20, 2001

For: REGULATED GROWTH FACTOR
DELIVERY FOR ENGINEERED
PERIPHERAL NERVE




Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: UTSC:646US/SLH

RECEIVED
FEB 14 2002
APR 03 2002
PATENT
TECH CENTER 1600/2500
FEB 14 2002
TECH CENTER 1600/2500

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 30, 2002	
Date	
	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10106337/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Steven L. Highlander", is written over a circular stamp or seal.

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 30, 2002

Form PTO-1449 (modified)		Atty. Docket No. UTSC:646US/SLH	Serial No. 09/910,681
List of Patents and Publications for Applicant		Applicant Gregory R.D. Evans <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: July 20, 2001	Group: 1614
(Use several sheets if necessary)			
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,797,368	1/10/89	Carter <i>et al.</i>	435	320	3/15/85
	A2	5,139,941	8/18/92	Muzyczka <i>et al.</i>	435	172.3	10/25/91
	A3	5,302,523	4/12/94	Coffee <i>et al.</i>	435	172.1	12/11/91
	A4	5,464,765	11/7/95	Coffee <i>et al.</i>	435	172.3	1/14/94
	A5	5,863,297	1/26/99	Walter <i>et al.</i>	623	16	10/8/96
	A6	5,939,323	8/17/99	Valentini <i>et al.</i>	435	395	5/28/97
	A7	5,977,204	11/2/99	Boyan <i>et al.</i>	523	113	4/11/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	⁰ EP 216453	4/1/87	Europe			
	B2	² WO 95/04132	2/9/95	PCT			
	B3	⁷ WO 95/24497	9/14/95	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	* Archibald <i>et al.</i> , "A collagen-based nerve guide conduit for peripheral nerve repair: An electrophysiological study of nerve regeneration in rodents and nonhuman primates," <i>J Comp Neurol</i> , 306:685-696, 1991.
	C2	* Carbonelli <i>et al.</i> , "A plasmid vector for isolation of strong promoters in Escherichia coli," <i>Fems Microbiology Letters</i> , 177:75-82, 1999.
	C3	* Chandler <i>et al.</i> , "DNA Sequences Bound Specifically by Glucocorticoid Receptor in vitro Render a Heterologous Promoter Hormone Responsive in vivo," <i>Cell</i> , 33:489-499, 1983.

25098493.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Atty. Docket No.

UTSC:646US/SLH

Serial No.

09/910,681

Applicant

Gregory R.D. Evans *et al.*

Filing Date:

July 20, 2001

Group:

1614

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	^o Chang <i>et al.</i> , "Foreign gene delivery and expression in hepatocytes using a hepatitis B virus vector," <i>Hepatology</i> , 14:134A, Abstract #307, 1991.
	C5	^o den Dunner <i>et al.</i> , "Light-microscopic and electron-microscopic evaluation of short-term nerve regeneration using a biodegradable poly(DL-lactide-ε-caprolacton) nerve guide," <i>Biomed Materials Research</i> , 31:105-115, 1996.
	C6	^o Evans <i>et al.</i> , "In vivo evaluation of poly(L-Lactic acid) porous conduits for peripheral nerve regeneration," <i>Biomaterials</i> , 20:1109-1115, 1999.
	C7	^o Fechheimer <i>et al.</i> , "Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading," <i>Proc Nat'l. Acad. Sci. USA</i> 84:8463-8467, 1987.
	C8	^o Gopal, "Gene transfer method for transient gene expression, stable transformation, and cotransformation of suspension cell cultures," <i>Mol. Cell. Biol.</i> 5:1188-1190, 1985.
	C9	^o Graham and Prevec, "Manipulation of adenovirus vectors," In. <i>Gene Transfer and Expression Protocols</i> , Murray, ed., Humana, New Jersey, vol. 7, 109-128, 1991.
	C10	^o Grunhaus and Horwitz, "Adenovirus as cloning vector," <i>Seminar in Virology</i> , 3:237-252, 1992.
	C11	^o Hempstead <i>et al.</i> , "Expression of functional nerve growth factor receptors after gene transfer," <i>Science</i> , 243:373-375, 1989.
	C12	^o Hesdorffer <i>et al.</i> , "Efficient gene transfer in live mice using a unique retroviral packaging line," <i>DNA Cell Biol.</i> , 9(10):713-723, 1990.
	C13	^o Kaneda <i>et al.</i> , "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," <i>Science</i> , 243:375-378, 1989.
	C14	^o Kato <i>et al.</i> , "Expression of hepatitis B virus surface antigen in adult rat liver," <i>J. Biol. Chem.</i> , 266(6):3361-3364, 1991
	C15	^o Klein <i>et al.</i> , "High-velocity microprojectiles for delivering nucleic acids into living cells," <i>Nature</i> , 327:70-73, 1987.
	C16	^o Le Gal La Salle <i>et al.</i> , "An adenovirus vector for gene transfer into neurons and glia in the brain," <i>Science</i> , 259:988-990, 1993.
	C17	^o Leitner <i>et al.</i> , "Enhancement of tumor-specific immune response with plasmid DNA replicon Vectors," <i>Cancer Res.</i> 60:51-55, 2000.

25098493.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

FEB 14 2002

RECEIVED

APR 03 2002

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSC:646US/SLHSerial No.
09/910,681Applicant
Gregory R.D. Evans *et al.*Filing Date:
July 20, 2001Group:
1614U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	² Macejak and Sarnow, "Internal initiation of translation mediated by the 5' leader of a cellular mRNA," <i>Nature</i> , 353:90-94, 1991.
	C19	⁴ Madison <i>et al.</i> , "Entubulation repair with protein additives increases the maximum nerve gap distance successfully bridged with tubular prostheses," <i>Brain Research</i> , 447:325-334 1988.
	C20	² Markowitz <i>et al.</i> , "A safe packaging line for gene transfer: Separating viral genes on two different plasmids," <i>J. Virol.</i> , 62:1120-1124, 1988.
	C21	¹ McCarty <i>et al.</i> , "Sequences Required for Coordinate Induction of Adeno-Associated Virus p19 and p40 Promoters by Rep Protein," <i>J. Virol.</i> , 65:2936-2945, 1991.
	C22	¹ McLaughlin <i>et al.</i> , "Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures," <i>J. Virol.</i> , 62:1963-1973, 1988.
	C23	⁶ Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," <i>Curr. Top. Microbiol. Immunol.</i> , 158:97-129, 1992.
	C24	¹ Pelletier and Sonenberg, "Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA," <i>Nature</i> , 334:320-325, 1988
	C25	¹ Ridgeway, "Mammalian expression vectors," In: Rodriguez and Denhardt, (ed.) <i>Vectors: A survey of molecular cloning vectors and their uses</i> . Stoneham: Butterworth, pp. 467-492, 1988
	C26	⁶ Roux <i>et al.</i> , "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses," <i>Proc Nat'l Acad. Sci. USA</i> , 86:9079-9083, 1989.
	C27	¹ Shelling and Smith, "Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene," <i>Gene Therapy</i> , 1:165-169, 1994.
	C28	¹ Tur-Kaspa <i>et al.</i> , "Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes," <i>Mol. Cell Biol.</i> , 6:716-718, 1986.
	C29	¹ Valentini <i>et al.</i> , "Collagen-and laminin-containing gels impede peripheral nerve regeneration through semipermeable nerve guidance channels," <i>Experimental neurology</i> , 98:350-356, 1987.
	C30	⁶ Walsh <i>et al.</i> , "Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector," <i>J. Clin. Invest.</i> , 94:1440-1448, 1994.

25098493.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED
RECEIVED

FEB 14 2002

APR 03 2002

TECH CENTER 1600/2900
TECH CENTER 1600/2900

Form PTO-1449 (modified)	Atty. Docket No. UTSC:646US/SLH	Serial No. 09/910,681
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gregory R.D. Evans <i>et al.</i>	
	Filing Date: July 20, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	Wang <i>et al.</i> , "Sleeve insertion and collagen coating improve nerve regeneration through vein conduits," <i>J Reconstruc Microsurg</i> , 9(1): 39-48, 1993.
	C32	Watanabe <i>et al.</i> , "Gene transfection of mouse primordial germ cells in vitro and analysis of their survival and growth control," <i>Experimental Cell Research</i> , 230:76-83, 1997.
	C33	Widmer <i>et al.</i> , "Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration," <i>Biomaterials</i> , 19:1945-1955, 1998.
	C34	Yang <i>et al.</i> , "In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment," <i>Proc Nat'l Acad Sci. USA</i> , 87:9568-9572, 1990.

25098493.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

FEB 14 2002

RECEIVED

APR 03 2002